Puneet Chandna, Consultant Precision Medicine at At Confidential, shared a post on LinkedIn:
”This first ASCO guideline explains when ctDNA blood tests should be used in cancer care and when traditional tissue biopsy is still essential. (ASCO Publications)
Blood is becoming the new biopsy, but evidence must remain the new standard.
The first ASCO guideline on circulating tumor DNA (ctDNA) marks a defining moment for precision oncology. It reminds us that innovation is valuable only when it changes patient outcomes and not simply because it detects more. ctDNA is a powerful complement to tissue biopsy, but not a replacement. The future belongs to evidence-driven precision medicine.”
Title: Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline
Authors: Christina M. Lockwood, Hans J. Messersmith, Annette S. Kim, Padma Sheila Rajagopal, Umang Swami, Rena Xian, Dara Aisner, Maria E. Arcila, Florence Kurttila, Christine M. Lovly, Jason D. Merker, Kanika G. Nair, Atara Isaiah Ntekim, Melanie Anne Sheen, Apostolia Maria Tsimberidou, Nicholas C. Turner, Stacy W. Gray
Other articles about CtDNA on OncoDaily.